Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
This project is supported by the Irish Government through IDA Ireland
Our centers are performing as expected or even better
Subscribe To Our Newsletter & Stay Updated
